TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Na
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva Pharmaceuticals and Royalty Pharma announced a funding agreement worth up to $500 million to accelerate clinical development of TEV-'408, an anti-IL-15 antibody candidate for vitiligo treatment. The deal includes $75 million for Phase 2b funding with an option for an additional $425 million for Phase 3 development. TEV-'408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, addressing a significant unmet medical need with limited current treatment options.

Insights
VYLD   neutral

Mentioned as launching tokenization initiatives without specific details about success or scale


TEVA   positive

Teva secured substantial funding ($500M) to accelerate development of a promising pipeline candidate, supporting its Pivot to Growth strategy. The partnership with a reputable funding partner and emerging positive Phase 1b data for an unmet medical need in vitiligo treatment represent significant strategic progress.